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A B S T R A C T
The vascular bioactivation of the antianginal drug nitroglycerin (GTN), yielding 1,2-glycerol dinitrate and
nitric oxide or a related activator of soluble guanylate cyclase, is catalyzed by aldehyde dehydrogenase-2
(ALDH2) in rodent and human blood vessels. The essential role of ALDH2 has been conﬁrmed in many
studies and is considered as general principle of GTN-induced vasodilation in mammals. However, this
view is challenged by an early report showing that diphenyleneiodonium, which we recently
characterized as potent ALDH2 inhibitor, has no effect on GTN-induced relaxation of bovine coronary
arteries (De La Lande et al., 1996). We investigated this issue and found that inhibition of ALDH2
attenuates GTN-induced coronary vasodilation in isolated perfused rat hearts but has no effect on
relaxation to GTN of bovine and porcine coronary arteries. This observation is explained by low levels of
ALDH2 protein expression in bovine coronary arteries and several types of porcine blood vessels. ALDH2
mRNA expression and the rates of GTN denitration were similarly low, excluding a signiﬁcant
contribution of ALDH2 to the bioactivation of GTN in these vessels. Attempts to identify the responsible
pathway with enzyme inhibitors did not provide conclusive evidence for the involvement of ALDH3A1,
cytochrome P450, or GSH-S-transferase. Thus, the present manuscript describes a hitherto unrecognized
pathway of GTN bioactivation in bovine and porcine blood vessels. If present in the human vasculature,
this pathway might contribute to the therapeutic effects of organic nitrates that are not metabolized by
ALDH2.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/bio c hem p har m1. Introduction
The antianginal drug nitroglycerin (GTN) causes vasodilation
through the activation of soluble guanylate cyclase (sGC), resulting
in accumulation of 30,50-cyclic guanosine monophosphate (cGMP)
in vascular smooth muscle. This effect is mediated by enzymaticAbbreviations: ALDH, aldehyde dehydrogenase; CB25, 1-{[4-(1,3-benzodioxol-5-
ylmethyl)-1-piperazinyl]methyl}-1H-indole-2,3-dione; cGMP, 30 ,50-cyclic guano-
sine monophosphate; DEA/NO, 2,2-diethyl-1-nitroso-oxyhydrazine; DMSO, di-
methyl sulfoxide; DPI, diphenyleneiodonium; DTPA, diethylenetriamine
pentaacetic acid; DTT, dithiothreitol; EDTA, ethylene diamine tetraacetic acid;
GDN, glycerol dinitrate; GTN, glycerol trinitrate (nitroglycerin); NAD, nicotinamide
adenine dinucleotide; L-NNA, NG-nitro-L-arginine; NO, nitric oxide; ODQ, 1H-
[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one; sGC, soluble guanylate cyclase..
* Corresponding author.
E-mail address: mayer@uni-graz.at (B. Mayer).
http://dx.doi.org/10.1016/j.bcp.2014.12.021
0006-2952/ 2015 The Authors. Published by Elsevier Inc. This is an open access articrelease of nitric oxide (NO) or a related species, which binds with
nanomolar afﬁnity to the prosthetic heme group of sGC. The
mechanism underlying bioactivation of GTN to yield NO has
remained controversial for several decades. Besides the non-
enzymatic reaction of GTN with cysteine [1,2] or ascorbate [3],
several enzymes were proposed to catalyze GTN bioactivation, in
particular GSH-S-transferase [4,5], cytochrome P450 [6,7], cyto-
chrome P450 reductase [8] and xanthine oxidase, which exhibits
nitrite reductase activity at low oxygen tension [9,10]. However,
the involvement of xanthine oxidase-catalyzed nitrite reduction
was later excluded [11], and neither of the other pathways appears
to fully explain GTN vasoactivity [12].
In 2002, Stamler and coworkers proposed aldehyde dehydroge-
nase-2 (ALDH2) as the key enzyme that catalyzes GTN bioactivation
[13], and meanwhile there is general agreement that this pathway
is essentially involved in GTN-induced relaxation in rodent andle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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GTN-induced relaxation by ALDH2 inhibitors [13] and the absence
of the high afﬁnity pathway of GTN vasodilation in ALDH2-deﬁcient
mice [15]. The main route of ALDH2-catalyzed denitration of GTN
yields 1,2-glycerol dinitrate (1,2-GDN) and inorganic nitrite, but our
data obtained with several ALDH2 mutants suggest that GTN
bioactivity is mediated by a minor pathway resulting in the direct
formation of NO [16].
The involvement of ALDH2 in GTN-induced relaxation has been
demonstrated for rabbit [13], rat [17–19], mouse [15,20], guinea
pig [21], and human [22,23] blood vessels, suggesting a general
principle of vascular GTN bioactivation in mammals. However, in
an early study Horowitz and coworkers showed that diphenyle-
neiodonium (DPI), which we recently characterized as potent
ALDH2 inhibitor [24], does not affect relaxation to GTN of bovine
coronary arteries [25]. In the present study we conﬁrm this
observation, extend it to porcine coronary arteries, and show that
ALDH2 expression is very low in bovine coronary arteries and
several types of porcine vessels. The results point to an ALDH2-
independent pathway of GTN bioactivation that may be relevant
for the pharmacology of organic nitrates, in particular the
isosorbide nitrates, which are not metabolized by ALDH2.
2. Materials and methods
2.1. Materials
Human ALDH2 was expressed in Escherichia coli BL21 (DE3) and
puriﬁed as described previously [26,27]. Ethylenediamine tetra-
acetic acid-(EDTA)-free CompleteTM Protease Inhibitor Cocktail
Tablets were from Roche Diagnostics GmbH (Vienna, Austria).
[2-14C]GTN (50 mCi/mmol) was from American Radiolabeled
Compounds, purchased through Hartmann Analytic GmbH
(Braunschweig, Germany). Nitro POHL1 ampoules (G. Pohl-
Boskamp GmbH & Co., Hohenlockstedt, Germany), containing
4.4 mM GTN in 250 mM glucose, were obtained from a local
pharmacy and diluted with distilled water. Unlabelled organic
nitrates used as standards in radio thin layer chromatography
(GTN, 1,2-GDN and 1,3-GDN) were purchased from LGC Standards
(Wesel, Germany). 2,2-Diethyl-1-nitroso-oxyhydrazine (DEA/NO)
and 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ) were
from Enzo Life Sciences (Lausen, Switzerland) purchased through
Eubio (Vienna, Austria). DEA/NO was dissolved and diluted in
10 mM NaOH. The selective ALDH3A1 inhibitor 1-{[4-(1,3-
benzodioxol-5-ylmethyl)-1-piperazinyl]methyl}-1H-indole-2,3-
dione (CB25) [28] was obtained from ChemBridge Corporation (San
Diego, CA, USA). All other chemicals were from Sigma–Aldrich
(Vienna, Austria), including 9,11-dideoxy-11a,9a-epoxymetha-
noprostaglandin F2a (U-46619), DPI, NG-Nitro-L-arginine (L-NNA)
and chloral hydrate. Stock solutions of ODQ (100 mM), DPI
(10 mM) and U-46619 (0.1 mM) were prepared in dimethyl
sulfoxide or ethanol and further diluted in buffer. Final concentra-
tion of organic solvents did not exceed 0.1%.
2.2. Animals and tissues
Sprague-Dawley rats (obtained from Charles River, Sulzfeld,
Germany) of either sex were housed at the local animal facility in
approved cages and kept on a regular 12-hour dark/light cycle.
They were fed standard chow (Altromin 3023; obtained from
Ko¨nigshofer Futtermittel (Ebergassing, Austria)) and received
water ad libitum. Animals were euthanized in a box that was
gradually ﬁlled with CO2 until no more vital signs (cessation of
respiration and circulation) were noticed. Subsequently, the thorax
of the animals was opened. The thoracic aorta (and for someexperiments heart and liver) were removed and placed in chilled
buffer.
Porcine and bovine hearts were obtained from a local abattoir
and immediately transported to the laboratory. The right coronary
artery was carefully explanted and immediately used for assess-
ment of vessel function.
2.3. Ring experiments (organ bath)
For isometric tension measurements, isolated blood vessels
were cut into rings of 3 mm length, and the rings suspended in 5-
ml organ baths, containing oxygenated Krebs–Henseleit buffer
(concentrations in mM: NaCl 118.4, NaHCO3 25, KCl 4.7, KH2PO4
1.2, CaCl2 2.5, MgCl2 1.2, D-glucose 10.1; pH 7.4) as previously
described in detail [24]. After equilibration for 60 min at the
optimal resting tension (rat aorta: 1 g; porcine coronary artery:
2 g; bovine coronary artery: 4 g), maximal contractile activity was
determined with a depolarizing solution containing
100 mM K+. Rings that did not elicit adequate and stable
contraction to high K+ were considered as being damaged and
omitted from the study. After washout, tissues were precontracted
with the thromboxane mimetic U-46619. Addition of 50 nM U-
46619 contracted rat aortas to 90% of contraction obtained with
100 mM K+, while 50 nM U-46619 contracted porcine and bovine
coronary arteries to 60% of maximal contraction. If indicated,
chloral hydrate (1 mM), DPI (0.3 mM), L-NNA (1 mM) or ODQ
(100 mM) were added simultaneously with U-46619 to the
preparation. After a stable tone had been reached (20 min),
cumulative concentration–response curves were established in
separate rings with GTN (0.1 nM–300 mM) or DEA/NO (1 nM–
10 mM). The contractile force corresponding to each agonist
concentration was recorded and expressed as percent of precon-
traction. For comparison of agonist potency in aortas and coronary
arteries, concentration–response curves to GTN and DEA/NO were
additionally established with rat aortic rings precontracted with
20 nM instead of 50 nM U-46619 (yielding 50% of maximal
contraction; see Legend to Fig. 2).
2.4. Measurement of coronary ﬂow in perfused isolated rat hearts
Hearts from euthanized animals were mounted on a heart
perfusion apparatus (Hugo Sachs Elektronik/Harvard Instruments,
March-Hugstetten, Germany) and retrogradely perfused at 37 8C
with oxygenated Krebs–Henseleit buffer at 80 mm Hg (constant
pressure perfusion) as previously described [21]. The following
cardiac parameters were monitored in unpaced hearts: coronary
ﬂow (as index of coronary arterial function) with a transonic ﬂow
probe, left-ventricular developed pressure via a ﬂuid-ﬁlled balloon
that was inserted into the left ventricle and connected to a pressure
transducer, and heart rate, derived electronically from the pressure
signal.
After equilibration for 30 min (baseline), coronary relaxation
was induced with GTN given as bolus injections through a sideline
in non-cumulative manner, resulting in ﬁnal concentrations of
1 nM to 100 mM (5 min per dose). After the last dose, GTN was
washed out for 30 min, and baseline was re-established. Thereaf-
ter, a concentration–response curve to DEA/NO (1 nM–10 mM) was
established (total duration of the experiment 120 min). To test for
the involvement of ALDH2, experiments were performed in the
absence and presence of 0.1 mM DPI, added to the perfusion buffer.
2.5. Immunoblotting
Freshly isolated aortas or coronary arteries were cleaned,
weighed and pre-digested with collagenase (1.5 mg/ml) in 10 mM
Tris-buffer, pH 7.4, containing 250 mM sucrose, 3 mM CaCl2,
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amphotericin B for 30 min at 37 8C. After incubation, tissues were
washed in phosphate-buffered saline and homogenized with a
Potter-Elvehjem glass or teﬂon homogenizer in 5–10 fold volumes
of 10 mM Tris-buffer, pH 7.4, containing 125 mM potassium
chloride, 5 mM ethylene glycol tetraacetic acid, 2 mM MgCl2 and
CompleteTM Protease Inhibitor Cocktail (Roche Diagnostics GmbH,
Vienna, Austria). Osmolarity was adjusted to 290 mosmol/l with
NaCl. Non-ﬁbrous liver tissues were homogenized directly after
isolation. Homogenates were centrifuged at 510  g and 4 8C for
5 min to remove tissue debris and then centrifuged at 20,800  g
and 4 8C for 10 min to separate membranes and organelles,
including mitochondria. Supernatants were regarded as cytosolic
fractions, the obtained pellets were washed in 0.4 ml buffer,
centrifuged again at 20,800  g and 4 8C for 10 min. The resulting
pellets are designated as mitochondrial fractions throughout the
paper. For preparation of total homogenates, tissues were weighed,
homogenized in a 10-fold volume of buffer and centrifuged at
510  g and 4 8C for 5 min Protein concentration was determined
with the Pierce BCATM Protein Assay Kit (Fisher Scientiﬁc Austria
GmbH, Vienna, Austria). Denatured samples (10–40 mg of protein)
were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis on 12% gels and transferred onto nitrocellulose
membranes. After blocking with 5% nonfat dry milk in phosphate-
buffered saline, containing 0.05% Tween-20 (v/v), for 1 h mem-
branes were incubated overnight at 4 8C with primary antibodies
against human ALDH2 (1:20,000; polyclonal, kindly provided by
Dr. Henry Weiner), b-actin (1:200,000; Sigma), citrate synthetase
(CS, 1:1000; Abcam) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH; 1:50,000; Sigma). After incubation of membranes
with horseradish peroxidase-conjugated anti-rabbit or anti-mouse
IgG (1:5000), immunoreactive bands were visualized by chemilu-
minescence using ECL Prime Western Blot Detection Reagent (GE
Healthcare, purchased via VWR, Vienna, Austria) and quantiﬁed
densitometrically using the E.A.S.Y. Win 32 software (Herolab,
Vienna, Austria).
2.6. Determination of ALDH mRNA expression
Total RNA was isolated from homogenized tissues (rat aorta,
porcine and bovine coronary arteries) using the GenEluteTMMam-
malian Total RNA Miniprep Kit (Sigma) including DNAse treatment
of samples. cDNA was synthesized using the High Capacity DNA
Reverse Transcription Kit (Applied Biosystems, Vienna, Austria).
Primers for mRNA expression analysis were designed on the basis
of published rat, porcine and bovine nucleic acid sequences of
GenBank (NCBI) using the Primer-BLAST software (Table 1).Table 1
PCR primers used for qPCR analysis.
Gene Forward primer Reverse p
Rat aorta
ALDH1A1 50-ttaaccctgcaactgaggag-30 50-caaaga
ALDH2 50-aacgtggtggtgatgaaagt-30 50-gtgacca
ALDH3A1 50-catcatgtacactgggagca-30 50-tccacga
Cyclophilin A 50-ctggtggcaagtccatctac-30 50-cccgcaa
Bovine coronary artery
ALDH1A1 50-caaaccagcagagcaaaccc-30 50-gagaag
ALDH2 50-aaccttccccacggtcaatc-30 50-ttcactg
ALDH3A1 50-gacccctctatccagagcca-30 50-gaagtgc
Cyclophilin A 50-aagactgagtggttggatg-3 50-gtcagca
Porcine coronary artery
ALDH2 50-acaaggaagatgtggacaggg-30 50-tctccag
ALDH3A1 50-agtcccgtgactacggaaga-30 50-ctccgta
Cyclophilin A 50-cgtcttcttcgacatcgccg-30 50-ctttctccAmpliﬁcation efﬁciency of the primers was determined by qPCR
analysis using serial dilutions of the cDNA template. Efﬁciency
was calculated from the slope of the curve using the following
equation: E = 10(1/slope) (Table 1). Real-time PCR analysis was
performed with 10 ng cDNA and primer concentrations of
100 nM using Power SYBR1 Green PCR Master Mix (Applied
Biosystems, Vienna, Austria). Reactions were carried out on a
7300 Real-Time PCR System (Applied Biosystems, Vienna,
Austria). Cycling conditions were as follows: 2 min at 50 8C,
10 min at 95 8C, 50 cycles of 15 s at 95 8C, and for 1 min at 60 8C.
Melting curve analysis consisted of the following steps: 15 s at
95 8C, 30 s at 60 8C, and 15 s at 95 8C. Data were analyzed and
calculated according to Pfafﬂ [29]. Data were calculated relative
to rat aortic ALDH2 mRNA expression after normalization to
cyclophilin A.
2.7. GTN denitration catalyzed by intact blood vessels
The rates of GTN denitration catalyzed by rat aortas as well as
porcine and bovine coronary arteries were determined as
formation of 1,2- and 1,3-GDN in the absence and presence of
the ALDH2 inhibitor chloral hydrate. Freshly removed arteries
were cleaned, weighed and cut into four pieces each, which were
equilibrated at 37 8C for 15 min in organ baths containing 5 ml of
oxygenated phosphate buffer (50 mM K2HPO4, 80 mM NaCl,
3 mM MgCl2, 2 mM EDTA and 1 mM NAD
+, pH 7.4). Afterwards,
pieces were transferred into a ﬁnal volume of 0.2 ml of the same
buffer, diced with scissors, and incubated for 10 min at 37 8C in
the presence of 2 mM 14C-labeled GTN and 2 mM dithiothreitol
(DTT). Reactions were terminated by ﬂash freezing the samples
twice in liquid nitrogen [30]. GTN and denitrated metabolites
were extracted twice with 1 ml diethyl ether, separated by thin
layer chromatography, and quantiﬁed by liquid scintillation
counting as described previously [18]. Blank values were
determined in the absence of tissue under identical conditions
and subtracted.
2.8. GTN denitration catalyzed by subcellular fractions of rat liver,
heart, and aorta
Freshly removed tissues were cleaned, weighed and homoge-
nized gently with a teﬂon potter in 10 mM Tris-buffer, pH 7.4,
containing 125 mM KCl, 5 mM ethylene glycol tetraacetic acid,
2 mM MgCl2, and Complete
TM Protease Inhibitor Cocktail. If
necessary, osmolarity was adjusted to 290 mosmol/l with NaCl.
Homogenates were centrifuged at 510  g and 4 8C for 5 min to
remove tissue debris and nuclei, followed by centrifugation atrimer GeneBank accession
no. (NCBI)
Efﬁciency
ctttcccaccattg-30 NM_022407 1.99
acctcagtggaac-30 NM_032416 1.86
tttggttctgaat-30 NM_031972 1.87
gtcaaagaaatta-30 NM_017101 2.01
aaatggctgcccct-30 NM_174239 1.91
ctctgtccacgtc-30 NM_001075367 1.82
cgggagttgatga-30 NM_001166513 2.77
atggtgatcttc-30 NM_178320 1.97
tgccgctaggt-30 NM_001044611 2.16
ggcgactttctgg-30 XM_005669258 2.17
ccagtgctcaga-30 NM_214353 1.91
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natants were regarded as cytosolic fractions, pellets were washed
with 0.4 ml buffer, centrifuged again at 20,800  g and 4 8C for
10 min, resuspended in equal volumes of buffer as cytosols and
used as mitochondrial fractions. The rates of GTN denitration were
determined as formation of 1,2- and 1,3-GDN as described
previously [18]. Subcellular fractions obtained from 10 to 20 mg
of tissue were incubated with 2 mM 14C-labeled GTN at 37 8C for
10 min in a ﬁnal volume of 0.2 ml of 50 mM potassium phosphate
buffer, pH 7.4, containing 3 mM MgCl2, 2 mM EDTA, 1 mM NAD
+,
and 2 mM DTT in the absence and presence of the ALDH2 inhibitor
chloral hydrate. Samples were analyzed for 14C-labeled 1,2-GDN as
described above.
2.9. Statistical analysis
Data are presented as mean values  SEM of n experiments.
Concentration–response curves established with different ring
segments from a single animal were averaged and counted as
individual experiment (n = 1). Individual concentration–response
curves were ﬁtted to a Hill-type model giving estimates of agonist
potency (EC50) and efﬁcacy (Emax). Analysis of variance (ANOVA) with
post hoc Bonferroni–Dunn test was used for comparison between
groups using StatView1 (Version 5.0). Signiﬁcance was assumed at
p < 0.05.Fig. 1. Effects of chloral hydrate, DPI, L-NNA and ODQ on relaxation of porcine and bovin
coronary arteries were precontracted with U-46619 (50 nM) in the absence or presenc
Cumulative concentration–response curves to GTN (A, B) or DEA/NO (C, D) were establ
averaged and counted as individual experiment (n = 1). The results shown are mean va3. Results
3.1. GTN causes ALDH2-independent relaxation of porcine and bovine
coronaries
Fig. 1 shows the relaxation of porcine (A) and bovine (B)
coronary arteries to GTN with EC50 values of 146  14 and
32  7 nM, respectively. Surprisingly, relaxation was not affected
by the non-selective ALDH inhibitor chloral hydrate or DPI, which we
have recently described as potent ALDH2 inhibitor [24]. Relaxation to
GTN of porcine coronary arteries which had been precontracted with
30 mM KCl instead of U-46619 was also insensitive to chloral hydrate
(data not shown). Since these results suggested that ALDH2 does not
contribute to GTN bioactivation in these vessels, we tested for the
potential involvement of endogenous NO [31] or a pathway unrelated
to sGC activation. However, the NO synthase inhibitor L-NNA did not
antagonize but even slightly potentiated the effect of GTN
(EC50 = 40  8 and 14  4 nM in porcine and bovine vessels,
respectively). Complete inhibition of relaxation by the sGC inhibitor
ODQ [32] strongly indicates that activation of sGC by GTN-derived NO
or a related species is essentially involved. The direct NO donor DEA/
NO caused relaxation of porcine and bovine coronary arteries with
EC50 values of 38  4 and 18  4 nM, respectively (panels C and D).
Again, chloral hydrate and DPI had no effect, relaxation was slightly
potentiated by L-NNA and blocked by ODQ.e coronary arteries to GTN and DEA/NO. Rings from porcine (A, C) and bovine (B, D)
e of chloral hydrate (CH; 1 mM), DPI (0.3 mM), L-NNA (1 mM), and ODQ (0.1 mM).
ished. Data obtained with two different ring segments from the same vessel were
lues  SEM of 3–5 (inhibitors) or 12–35 (controls) experiments (*p < 0.05).
Fig. 2. Effects of precontraction levels on relaxation of rat aortic rings to GTN and DEA/NO. Concentration response to GTN (A) and DEA/NO (B) of rat aortic rings precontracted
with 50 nM (open symbols) or 20 nM (ﬁlled symbols) U-46619, resulting in precontraction levels of 91  5% and 44  6% (A) and 83  7% and 42  4% (B), respectively. The
corresponding EC50 values were 81.2  38 and 8.3  2.1 nM (A) and 79.4  38 and 15.4  5.4 nM (B). Data are mean values  SEM of ﬁve experiments (*p < 0.05).
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others with rat and mouse aortas, the present data apparently
point to signiﬁcantly higher GTN and NO sensitivity of porcine and,
in particular, bovine coronary arteries. Moreover, the typical
biphasic concentration–response to GTN observed with the rodent
vessels was absent. This difference is probably a consequence of
the lower level of precontraction applied in the experiments with
coronary arteries. As illustrated in Fig. 2, both GTN (A) and DEA/NO
(B) dilated rat aortic rings with 5- to 10-fold higher potency when
the precontraction level was reduced from 80 to 90% (as typically
applied) to about 40%. Note that potentiation of the GTN effect led
to virtually complete relaxation through the high afﬁnity pathway.
Regardless of precontraction levels, the potency of GTN relative
to that of DEA/NO varied considerably within species. In rat aorta,
the high afﬁnity pathway of GTN-induced relaxation exhibited an
EC50 of 86  5 nM as compared to 183  22 nM determined for DEA/
NO (data not shown). Thus, GTN was about 2-fold more potent than
DEA/NO in rat aorta, presumably due to site-speciﬁc intracellular
release of GTN-derived NO or a related bioactive species. In contrast,
GTN was about 4- and 2-fold less potent than DEA/NO in porcine and
bovine coronaries (ratios of EC50 values = 0.26 and 0.56, respectively).
Thus, the ALDH2-independent GTN bioactivation in porcine and
bovine blood vessels appears to take place with around 5-fold lower
GTN potency than ALDH2-mediated relaxation.
In view of the overwhelming evidence for an essential role of
ALDH2 for GTN bioactivation in rodent and human blood vessels,Fig. 3. Effects of ALDH2 inhibition on coronary vasodilation induced by GTN and DEA/NO i
Hg in the absence or presence of 0.1 mM DPI. Increase of coronay ﬂow, reﬂecting microva
values  SEM of six hearts per group. *p < 0.05 for 109 to 105 M GTN (panel A).the ALDH2-independent effects of the nitrate in porcine and bovine
coronary arteries were unexpected. To ﬁnd out whether this is due
to a species difference or reﬂects a speciﬁc feature of coronary
arteries, we used isolated rat hearts perfused in the Langendorff
mode to test for the involvement of ALDH2 in coronary relaxation
to GTN. Fig. 3 shows that the increase in coronary ﬂow caused by
GTN was markedly inhibited by the ALDH2 inhibitor DPI (panel A),
whereas relaxation to DEA/NO was not affected (panel B). Thus, the
striking difference between rodent and porcine/bovine blood
vessels is independent of the vascular bed and apparently due to a
species difference in the molecular mechanism underlying
vascular GTN bioactivation.
3.2. ALDH2 protein and mRNA expression in porcine and bovine blood
vessels
To shed light on this issue, we studied ALDH2 expression in
these blood vessels by quantitative immunoblotting using human
ALDH2 as a standard protein. As shown in Fig. 4A, homogenates of
rat aorta contained 4.6  0.65 ng of ALDH2 per mg of total protein.
Expression of ALDH2 was much lower in porcine and bovine coronary
arteries (0.04  0.02 and 0.51  0.08 ng/mg of total protein). A
representative blot is shown in Fig. 4B. The subcellular distribution
of ALDH2 is shown in Fig. 4C (summary data) and Fig. 4D
(representative blot). Rat aorta contained 16.4  1.73 and
2.0  0.31 ng of ALDH2 per mg wet weight in cytosolic andn isolated perfused rat hearts. Hearts were perfused at a constant pressure of 80 mm
scular vasodilation, caused by GTN (A) or DEA/NO (B) was recorded. Data are mean
Fig. 4. ALDH2 expression in liver and blood vessels of rats, pigs, and cows. (A) ALDH2 expression in rat aorta (RA), porcine coronary arteries (PCA), and bovine coronary arteries
(BCA) (n = 3). (B) Representative Western blot of total homogenates (30 mg of protein), showing ALDH2 (54 kDa) and b-actin (43 kDa). (C) Subcellular distribution of ALDH2 in
RA, PCA, and BCA (n = 4–6). (D) Representative Western blot of mitochondrial (M) and cytosolic (C) fractions (25 mg of protein each), showing ALDH2 (54 kDa) and b-actin
(43 kDa). Citrate synthetase (52 kDa) and prohibitin (30 kDa) as well as GAPDH (37 kDa) are shown as mitochondrial and cytosolic marker proteins, respectively. Note the
unequal protein yields obtained in the course of fractionation (shown in the inset to panel C), precluding estimation of protein distribution by visual inspection of band
intensities. (E) Expression of ALDH2 in rat liver (RL), rat aorta (RA), and porcine liver (PL), as well as the following porcine blood vessels: coronary artery (PCA), liver artery
(PLA), renal artery (PRA), and splenic artery (PSA) (n = 4). (F) Representative Western blots of total homogenates showing ALDH2 (54 kDa) and b-actin (43 kDa). Puriﬁed
human ALDH2 (25 ng) was used as standard (S) for protein quantiﬁcation. Summary data are expressed as ng ALDH2 per mg total protein or mg wet weight and represent
mean values  SEM of the number of experiments indicated in panel descriptions.
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cytosolic localization of ALDH2 in rodent blood vessels observed
previously [17,33]. Expression levels were considerably lower in the
bovine vessels (3.0  0.69 and 1.5  0.25 ng/mg in cytosolic and
mitochondrial fractions, respectively). In porcine coronary arteries
ALDH2 was hardly detectable (<0.5 ng/mg). Note that pronounceddifferences in the recovery of cytosolic and mitochondrial protein
(shown in the inset to Fig. 4C) may mislead judgment of band
intensities in the blot (Fig. 4D), which was loaded with identical
amounts of cytosolic and mitochondrial protein.
To see whether low ALDH2 expression is a peculiarity of
coronary arteries, we measured the protein levels in several types
Fig. 5. Relative mRNA expression of ALDH isoforms in rat aorta, and porcine and
bovine coronary arteries. Total RNA was isolated from rat aortas (n = 5), and bovine
and porcine coronary arteries (n = 5–6). mRNA levels were determined by SYBR
Green-based qPCR, and expression levels are calculated relative to the ALDH2
mRNA levels of rat aortas after normalization to cyclophilin A. Data are mean
values  SEM of 5–6 experiments.; n.d., not detectable (<0.0001%). ALDH1A1 mRNA
was not determined in PCA. *p < 0.05 compared with ALDH2 in rat aorta; #p < 0.05
compared with ALDH1A1 in rat aorta.
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expression levels in rat liver, rat aorta, and porcine liver. As shown
in Fig. 4E, the highest expression levels were found in liver,
containing about 150 (rat) and 40 (pig) ng/mg wet weight. Rat
aorta expressed about 40 ng of ALDH2 per mg tissue, whereas
expression levels were below 5 ng/mg in all porcine arteries
studied (coronary, liver, renal, and splenic artery). The data on
protein levels agreed well with ALDH2 mRNA expression (Fig. 5),
which was hardly detectable in porcine coronary arteries (0.01%
of rat aorta) and about 18% of rat aortic levels in bovine coronary
arteries. Expression levels of ALDH1A1 and ALDH3A1, respectively,
were about 0.05 and 3% of the ALDH2 levels in rat aorta, and not or
hardly detectable in porcine and bovine coronary arteries.
3.3. Low rates of GTN denitration in porcine and bovine coronaries
The rates of GTN denitration were assayed as formation of 1,2-
GDN and 1,3-GDN by blood vessel homogenates or subcellular
fractions. For comparison and validation of the method, we studied
GTN denitration by rat liver, aorta and heart in the absence and
presence of chloral hydrate. As shown in Fig. 6A, similar
denitration activities were measured in cytosolic and mitochon-
drial fractions of rat liver, but only mitochondrial denitration was
sensitive to chloral hydrate, conﬁrming that mitochondrial ALDH2Fig. 6. GTN denitration activity of vascular and non-vascular tissues. GTN denitration wa
(CH; 1 mM) with 2 mM [14C]GTN at 37 8C for 10 min in 0.2 ml of 50 mM potassium phosph
1,2-GDN was extracted and analyzed by radio thin layer chromatography as described in
obtained from 10 to 20 mg of rat liver, aorta, and heart. Data are mean values  SEM of 4
coronary arteries (PCA), and bovine coronary arteries (BCA) in the absence and presence ocatalyzes GTN denitration in liver. In contrast, ALDH2-catalyzed
GTN denitration activity was almost exclusively cytosolic in rat
aorta and mainly cytosolic in rat heart. As shown in Fig. 6B, the
rates of GTN denitration measured in pieces of equilibrated intact
pig and bovine coronary arteries were markedly lower than in rat
aortic rings. These results agree well with the low levels of ALDH2
protein and mRNA expression in these blood vessels. The rates of
1,3-GDN formation were very low under all experimental
conditions and are not shown for the sake of clarity.
3.4. Attempts to identify the pathway of GTN bioactivation
In search for possible enzymatic pathways of GTN bioactivation
on porcine and bovine coronary arteries we considered the
involvement of ALDH3A1 [34], cytochrome P450, GSH-S-transfer-
ase, g-glutamylcysteine synthetase, and xanthine oxidase.
The selective ALDH3A1 inhibitor CB25 [28] inhibited aldehyde
dehydrogenase activity in homogenates of rat eyes, which contain
large amounts of ALDH3A1 [35], with an IC50 of 5.7  2.2 mM but
had no effect on GTN- or DEA/NO-induced relaxation of rat aorta or
coronary arteries from pigs and cows (data not shown).
The cytochrome P450 inhibitor 7-ethoxyresoruﬁn (2 mM) had
no effect on relaxation induced by either GTN or DEA/NO. SKF-
525A (proadifen, 0.05–0.5 mM) relaxed the vessels in the absence
of donors, precluding further testing. Ketoconazole (10 mM)
caused a signiﬁcant 2-fold rightward shift of the GTN response
without affecting relaxation to DEA/NO. Although this ﬁnding
suggests a minor contribution of a cytochrome P450, this pathway
is certainly not the major route of ALDH2-independent GTN
bioactivation in porcine coronary arteries.
The GSH-S-transferase inhibitor bromosulfophthalein (1 mM)
blocked contraction to U-46619 and inhibited relaxation of K+-
contracted vessels to both GTN and DEA/NO. Ethacrynic acid
(0.1 mM) had no effect on relaxation of either donor, and 2,4-
dinitrochlorobenzene (0.4 mM) caused unstable contractions,
precluding further studies. Finally, inhibition of g-glutamylcys-
teine synthetase and xanthine oxidase with buthionine sulfox-
imine (10 mM) and allopurinol (0.1 mM), respectively, had no
effect on relaxation to GTN or DEA/NO (data not shown).
Finally, we considered a possible direct action of GTN on large
conductance Ca2+-activated K+ channels using the established
inhibitor iberiotoxin [36]. The drug inhibited relaxation to GTN and
DEA/NO in a similar manner (data not shown), conﬁrming that
large conductance Ca2+-activated K+ channels contribute to NO-
triggered relaxation [37]. However, the data provide no evidence
for a speciﬁc involvement of these channels in GTN-induced
vasodilation.s measured by incubation of tissues in the absence and presence of chloral hydrate
ate buffer, pH 7.4, containing 3 mM MgCl2, 2 mM EDTA, 1 mM NAD
+, and 2 mM DTT.
 Section 2. A, Rates of 1,2-GDN formation by cytosolic and mitochondrial fractions
–5 independent experiments. B, Rates of 1,2-GDN formation by rat aorta (RA), porcine
f 1 mM CH. Data are mean values  SEM of three independent experiments.
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Numerous studies have conﬁrmed the essential role of ALDH2 in
vascular GTN bioactivation, originally proposed by Stamler and
coworkers in 2002 [13]. Besides inhibition of GTN-induced
relaxation by various ALDH2 inhibitors, including non-selective
compounds such as chloral hydrate and cyanamide [13], as well as
the ALDH2-selective inhibitors daidzin [3,38], and DPI [24], loss of
the high afﬁnity pathway of GTN-induced vasodilation upon
deletion of the ALDH2 gene in mice [15] provided conclusive
evidence for the involvement of ALDH2 in GTN bioactivation. Since
similarresultswere obtainedwith bloodvessels fromseveral rodent
species (mouse, rat, guinea pig) as well as human arteries [22] and
veins [23], the ALDH2 reaction is widely considered as a general
principle of GTN bioactivation in mammalian vascular tissue.
However, in the 1990s Horowitz and coworkers reported that
DPI, which we recently identiﬁed as potent ALDH2 inhibitor, had
no effect on GTN-induced relaxation of bovine coronary arteries
[25]. In view of current knowledge this observation is surprising
and hard to reconcile with the ALDH2 hypothesis of GTN
bioactivation. The present study explains this astounding obser-
vation as a consequence of low ALDH2 expression and GTN
denitration activity. The protein was hardly detectable in porcine
coronary arteries, while signiﬁcant amounts were found in the
bovine vessels (albeit still much lower than in rat aorta). A similar
pattern was observed for the rates of denitration, which were high
in rat aorta and very low in porcine coronaries, while bovine
coronaries exhibited about 50% of the activity measured with rat
aorta. Based on this observation one might expect a signiﬁcant
contribution of ALDH2 to relaxation of bovine vessels, which was
not observed. However, the difference is more pronounced after
subtraction of ALDH2-independent denitration, yielding rates of
0.84 and 0.23 pmol min1 mg1 for rat aorta and bovine coronar-
ies, respectively. Moreover, there was a signiﬁcant difference in the
subcellular distribution of ALDH2 in the two types of blood vessels.
While about 90% of the protein was cytosolic in rat aorta, equal
amounts of ALDH2 were found in cytosolic and mitochondrial
fractions of bovine coronary arteries (cf. Fig. 4C). Since cytosolic
expression of ALDH2 appears to be essential for vascular GTN
bioactivation [33], signiﬁcant mitochondrial localization of the
protein may further reduce the fraction of enzyme available for
GTN bioactivation in the bovine vessels. We cannot exclude,
however, a minor contribution of ALDH2 to relaxation that was not
detectable in the organ bath experiments.
Virtually complete inhibition of GTN-induced relaxation by
ODQ indicates that vasodilation was caused by activation of sGC.
Since GTN does not activate sGC directly, the effect apparently
involves an enzymatic or non-enzymatic reaction yielding a NO-
like bioactive species together with denitrated metabolites. At a
ﬁrst glance, the low denitration rates we observed with porcine
and coronary arteries seem to be inconsistent with this assump-
tion. However, we have previously shown that ALDH2-catalyzed
NO formation accounts for only about 5% of total GTN turnover
[16]. Thus, low rates of denitration could be accompanied by
sufﬁciently high rates of bioactivation in an efﬁcient pathway of
GTN denitration that yields stoichiometric amounts of NO or a
related sGC activator.
Activation of endothelial NO synthase by GTN itself was
considered as alternative explanation for GTN bioactivity
[31]. However, the non-selective NO synthase inhibitor L-NNA
did not antagonize but slightly potentiated the effect of GTN,
excluding the involvement of endogenous NO synthesis. The
observed leftward shift of the response to DEA/NO and GTN in the
presence of L-NNA was relatively small and not further investigat-
ed. The short time frame of the experiments excludes up-
regulation of sGC expression, but it is conceivable that L-NNAblocked inactivation of NO by superoxide, which may be generated
by uncoupled NO synthase in GTN-exposed blood vessels [39].
We speculated that ALDH2-independent GTN bioactivation in
porcine and bovine coronary arteries might be identical to the low-
afﬁnity pathway mediating GTN vasodilation in ALDH2-deﬁcient
murine blood vessels. Comparison of GTN potency in vessels
obtained from different species was hampered by a pronounced
effect of precontraction levels. Lowering precontraction levels of
rat aortic rings by about 50%, to mimic the levels applied to porcine
and coronary arteries, led 5- to 10-fold potentiation of the effects of
GTN and DEA/NO (cf. Fig. 2). Therefore, we calculated GTN potency
relative to the potency of DEA/NO. The ratios of the respective EC50
values suggest that the ALDH2-independent porcine and bovine
pathways exhibit about 5-fold lower potency than the ALDH2-
catalyzed reaction in rodents. Published data with ALDH2
knockout mice, however, point to a more than 100-fold difference
in potency of the high and low afﬁnity pathways (EC50 = 0.1 and
12 mM, respectively; [15]), indicating that the ALDH2-indepen-
dent reaction described here is not the same that is involved in the
low afﬁnity effects of GTN in rodents.
Thus, GTN appears to be bioactivated in porcine and bovine
blood vessels through an unknown reaction not involving ALDH2.
Obviously, it would be interesting to identify the responsible
enzyme. Based on a recent report [34], we considered ALDH3A1 as
potential candidate. Although chloral hydrate is generally believed
to be a non-selective ALDH inhibitor, we found no conclusive
evidence showing that this drug inhibits ALDH3A1. Therefore, we
tested the selective ALDH3A1 inhibitor CB25 [28], but observed no
effect on GTN-induced relaxation of rat aorta or porcine and bovine
coronary arteries. These results, which agree well with the lack of
signiﬁcant ALDH3A1 mRNA expression levels (cf. Fig. 5) in these
blood vessels, appear to exclude a signiﬁcant contribution of
ALDH3A1 to vascular GTN bioactivation.
In addition, several compounds interfering with bioactivation
pathways proposed previously, in particular cytochrome P450 and
GSH-transferase, had no considerable effects or were unsuitable
for various reasons. Thus, we attempted to characterize this
pathway biochemically and measured GTN-induced cGMP accu-
mulation in homogenates and subcellular fractions of porcine
coronary arteries with and without exogenously added sGC
puriﬁed from bovine lung. However, GTN sensitivity was almost
completely lost upon homogenization of the tissue, partly due to
SOD- and DPI-insensitive scavenging of NO (Kollau, A., Neubauer,
A. Russwurm, M., Koesling, D. and Mayer, B.; unpublished results).
Further work is going on in our laboratory to settle this issue.
Taken together, our results provide evidence for an efﬁcient and
potent ALDH2-independent pathway of GTN bioactivation in
porcine and bovine coronary arteries. If present in human blood
vessels, this pathway might contribute to the therapeutic effect of
organic nitrates that are not metabolized by ALDH2.
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